-

07:15:26 PM

ETON Stock News

ETON - Eton Pharmaceuticals Inc

03/16/23 4:01 PM

Nasdaq : ETON

earnings

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq:

RHEA-AI

neutral

03/15/23 6:50 AM

Nasdaq : ETON

acquisition

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and

RHEA-AI

neutral

03/07/23 4:05 PM

Nasdaq : ETON

conferencesearnings

Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March

RHEA-AI

neutral

01/11/23 6:50 AM

Nasdaq : ETON

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused

RHEA-AI

very positive

11/10/22 4:05 PM

Nasdaq : ETON

earnings

Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results

Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022 Strong sales growth of ALKINDI SPRINKLE® and Carglumic Acid Third commercial product, Betaine Anhydrous, added to rare disease portfolio DEER PARK, Ill., Nov. 10, 2022

RHEA-AI

very positive

11/02/22 4:05 PM

Nasdaq : ETON

conferencesearnings

Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November

RHEA-AI

neutral

10/18/22 6:50 AM

Nasdaq : ETON

conferences

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will

RHEA-AI

neutral

09/13/22 9:00 AM

Nasdaq : ETON

acquisition

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the

RHEA-AI

very positive

08/30/22 4:05 PM

Nasdaq : ETON

conferences

Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will

RHEA-AI

neutral

08/11/22 4:01 PM

Nasdaq : ETON

earnings

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

Total Q2 2022 revenue of $7.4 million, up 139% from prior year Recently launched ALKINDI SPRINKLE ® and Carglumic Acid continue to show robust growth Divestiture of hospital products division to focus on rare disease strategy U.S. Food and Drug Administration (FDA) Approval of Zonisade™ (zonisamide

RHEA-AI

neutral

1 2 3 4 5 6 Next